1. EP-1704 A 2D reusable OSL-film for class solution specific QA of large modulated fields in the PART trial. (April 2019) Authors: De Roover, R.; Berghen, C.; De Meerleer, G.; Depuydt, T.; Crijns, W. Journal: Radiotherapy and oncology Issue: Volume 133(2019)Supplement 1 Page Start: S917 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. MO-0310 From Patient Reported Experience Measures (PREMs) to improvement actions at the Radiotherapy dept. (May 2022) Authors: Benazzouz, C.; Callens, D.; Verstraete, J.; Oldenburger, E.; Vanhaecht, K.; Berghen, C. Journal: Radiotherapy and oncology Issue: Volume 170(2022)Supplement 1 Page Start: S271 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PD-0850 Adjuvant radiotherapy after cystectomy for patients with bladder cancer: a phase II trial. (August 2021) Authors: Fonteyne, V.; Dirix, P.; Van Praet, C.; Berghen, C.; Albersen, M.; Junius, S.; Liefhooghe, N.; Noé, L.; De Meerleer, G.; Ost, P.; Decaestecker, K. Journal: Radiotherapy and oncology Issue: Volume 161(2021)supplement Page Start: S683 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PO-0856 Metastasis-directed therapy for oligoprogressive castration refractory prostate cancer. (April 2019) Authors: Berghen, C.; Joniau, S.; Ost, P.; Poels, K.; Everaerts, W.; Haustermans, K.; De Meerleer, G. Journal: Radiotherapy and oncology Issue: Volume 133(2019)Supplement 1 Page Start: S451 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PO-1200: Multimodality treatment for M1a prostate cancer: toxicity and early oncological results. (November 2020) Authors: Berghen, C.; Joniau, S.; Devos, G.; Poels, K.; Haustermans, K.; De Meerleer, G. Journal: Radiotherapy and oncology Issue: Volume 152(2020)Supplement 1 Page Start: S632 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PO-1201: Oligorecurrent prostate cancer treated with metastasis-directed therapy: oncological outcomes. (November 2020) Authors: Devos, G.; Berghen, C.; Joniau, S.; Poels, K.; Haustermans, K.; Rans, K.; De Meerleer, G. Journal: Radiotherapy and oncology Issue: Volume 152(2020)Supplement 1 Page Start: S633 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PO-1406 Hematological toxicity in pN1 prostate cancer patients treated with extended field irradiation. (May 2022) Authors: Berghen, C.; Laenen, A.; De Roover, R.; Dierickx, D.; Joniau, S.; Rans, K.; Crijns, W.; Baten, E.; Dumez, H.; Everaerts, W.; De Meerleer, G. Journal: Radiotherapy and oncology Issue: Volume 170(2022)Supplement 1 Page Start: S1192 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PO-1495 Protons versus photons for oligometastatic prostate cancer: a planning comparison. (May 2022) Authors: Rans, K.; De Meerleer, G.; Berghen, C.; Poels, K. Journal: Radiotherapy and oncology Issue: Volume 170(2022)Supplement 1 Page Start: S1272 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Salvage Radiotherapy for Prostate Cancer. Issue 3 (March 2020) Authors: Rans, K.; Berghen, C.; Joniau, S.; De Meerleer, G. Journal: Clinical oncology Issue: Volume 32:Issue 3(2020) Page Start: 156 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗